IP Library Granted Patent US 12,612,621
Granted Patent B2
US 12,612,621 · App. 18/402,273 · Granted Apr 28, 2026

Methods of selecting binding reagents

Inventor: Parag Mallick (San Mateo, CA)
Assignee: Nautilus Subsidiary, Inc.
C12N15/1055G01N33/6845
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,612,621
App. No.
18/402,273
Granted
Apr 28, 2026
Kind
B2
Abstract

Methods and systems are provided herein for selecting an affinity reagent which binds a desired peptide epitope in a plurality of sequence contexts. The method relies on obtaining a peptide library, each peptide having the sequence αXβ, wherein X is the desired peptide epitope, wherein each of α and β comprise an amino acid, using the peptide library to select an affinity reagent.

Claims (31)

1 . A method for characterizing an affinity reagent which binds a desired peptide epitope in a plurality of proteins, the method comprising:

obtaining a peptide library comprising a variety of sequence contexts, each peptide of the peptide library comprising the sequence αXβ, wherein X is the desired peptide epitope, wherein X is a sequence of two to seven amino acids, wherein each of α and β comprises at least one amino acid, and wherein each of α and β varies amongst the variety of sequence contexts within the peptide library;

screening a library of different affinity reagents against the peptide library to obtain the affinity reagent from the library of different affinity reagents which binds the desired peptide epitope X in at least 10% of the variety of the sequence contexts;

obtaining binding measurements between the affinity reagent from the library of affinity reagents and a plurality of known protein sequences; and

based upon the binding measurements of the affinity reagent from the library of affinity reagents to the plurality of known protein sequences, determining a model for the affinity reagent, wherein the model infers a binding probability of the affinity reagent from the library of affinity reagents to any protein given a sequence of the protein.

2 . The method of claim 1 , wherein at least one of α and β further comprises a linker.

3 . The method of claim 2 , wherein the linker is attached to a detection moiety.

4 . The method of claim 2 , wherein the linker is attached to a solid support.

5 . The method of claim 1 , wherein α comprises at least two amino acids.

6 . The method of claim 1 , wherein α comprises at least three amino acids.

7 . The method of claim 1 , wherein β comprises at least two amino acids.

8 . The method of claim 1 , wherein β comprises at least three amino acids.

9 . The method of claim 1 , wherein X is a sequence of three amino acids.

10 . The method of claim 1 , wherein the affinity reagent comprises an antibody or antibody fragment.

11 . The method of claim 1 , wherein the affinity reagent comprises an aptamer.

12 . The method of claim 1 , wherein the affinity reagent comprises a peptide.

13 . The method of claim 1 , further comprising screening the affinity reagent from the library of affinity reagents for binding to a library of n-mer peptide sequences, wherein the n-mer peptide sequences comprise two to ten amino acids.

14 . The method of claim 13 , wherein peptides of the library of n-mer peptide sequences comprise the sequence αXβ.

15 . The method of claim 1 , wherein a protein sequence of the plurality of known sequences contains the desired peptide epitope X.

16 . The method of claim 1 , wherein a protein sequence of the plurality of known protein sequences does not contain the desired peptide epitope X.

17 . The method of claim 1 , wherein the variety of sequence contexts comprises at least 400 sequence contexts.

18 . The method of claim 1 , wherein the affinity reagent from the library of affinity reagents binds the desired peptide epitope X in at least 10% of all longer peptides containing the desired peptide epitope X of the variety of the sequence contexts.

19 . The method of claim 1 , wherein the affinity reagent from the library of affinity reagents binds the desired peptide epitope X in at least 15% of the variety of the sequence contexts.

20 . The method of claim 1 , wherein individual affinity reagents of the library of different affinity reagents are immobilized to one or more substrates.

21 . The method of claim 1 , wherein at least one of α and β further comprises a modification selected from the group consisting of a N-terminal modification, a C-terminal modification, a positively-charged group, a negatively-charged group, a hydrophobic group, a sugar, and a nonnaturally occurring amino acid.

22 . The method of claim 1 , wherein the plurality of known protein sequences comprises at least 50 different protein sequences.

23 . The method of claim 1 , wherein the plurality of known protein sequences is provided on an array.

24 . The method of claim 23 , wherein a location of the array contains multiple copies of a protein sequence of the plurality of known protein sequences.

25 . The method of claim 23 , wherein a protein sequence of the plurality of known protein sequences is present at multiple locations of the array.

26 . The method of claim 1 , wherein determining the model for the affinity reagent comprises: (i) providing detected presence or absence of binding of the affinity reagent from the library of affinity reagents to the plurality of known protein sequences to a training algorithm; and (ii) calculating with the training algorithm for a plurality of protein sequences a probability of the affinity reagent from the library of affinity reagents binding to each protein sequence of the plurality of protein sequences.

27 . The method of claim 26 , wherein the plurality of protein sequences comprises known protein sequences of a proteome.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 5, 2026
From: MALLICK, PARAG
To: NAUTILUS SUBSIDIARY, INC.
Reel/Frame 073708/0322 →
Continuity (4)
Continuation 16791456 · Feb 14, 2020
Continuation PCTUS2018000364 · Aug 20, 2018
Provisional Application 62547699 · Aug 18, 2017
Related Publication 20240158782A1 · May 16, 2024
References Cited (205)
US 5324633A · Fodor et al. · 1994 [cited by applicant]
US 5445934A · Fodor et al. · 1995 [cited by applicant]
US 5695934A · Brenner · 1997 [cited by applicant]
US 5849878A · Cantor et al. · 1998 [cited by applicant]
US 5863722A · Brenner · 1999 [cited by applicant]
US 5888737A · Dubridge et al. · 1999 [cited by applicant]
US 5919626A · Shi et al. · 1999 [cited by applicant]
US 6140489A · Brenner · 2000 [cited by applicant]
US 6175002B1 · Dubridge et al. · 2001 [cited by applicant]
US 6391625B1 · Park et al. · 2002 [cited by applicant]
US 6589726B1 · Butler et al. · 2003 [cited by applicant]
US 6610482B1 · Fodor et al. · 2003 [cited by applicant]
US 6720595B2 · Clevenger et al. · 2004 [cited by applicant]
US 6806361B1 · Kajisa et al. · 2004 [cited by applicant]
US 6824866B1 · Glazer et al. · 2004 [cited by applicant]
US 6998241B2 · Boga · 2006 [cited by applicant]
US 7022515B2 · Herron et al. · 2006 [cited by applicant]
US 7148058B2 · Charych et al. · 2006 [cited by applicant]
US 7158224B2 · Montagu · 2007 [cited by applicant]
US 7239860B2 · Stoks · 2007 [cited by applicant]
US 7252954B2 · Wang et al. · 2007 [cited by applicant]
US 7545496B2 · Prins et al. · 2009 [cited by applicant]
US 7635562B2 · Harris et al. · 2009 [cited by applicant]
US 7794799B1 · Kim et al. · 2010 [cited by applicant]
US 7842793B2 · Rothemund · 2010 [cited by applicant]
US 7932060B2 · Nadeau et al. · 2011 [cited by applicant]
US 8133719B2 · Drmanac et al. · 2012 [cited by applicant]
US 8467061B2 · Mccaffrey et al. · 2013 [cited by applicant]
US 8501923B2 · Rothemund · 2013 [cited by applicant]
US 8680483B2 · Haga et al. · 2014 [cited by applicant]
US 8865077B2 · Chiou et al. · 2014 [cited by applicant]
US 8951781B2 · Williamson et al. · 2015 [cited by applicant]
US 9193996B2 · Buermann et al. · 2015 [cited by applicant]
US 9340416B2 · Maune et al. · 2016 [cited by applicant]
US 9528984B2 · Mitra · 2016 [cited by applicant]
US 9606058B2 · Rothberg et al. · 2017 [cited by applicant]
US 9678012B2 · Rothberg et al. · 2017 [cited by applicant]
US 9880175B2 · Mitra · 2018 [cited by applicant]
US 9921157B2 · Rothberg et al. · 2018 [cited by applicant]
US 10175248B2 · Mitra · 2019 [cited by applicant]
US 10330598B2 · Schleipen et al. · 2019 [cited by applicant]
US 10351909B2 · Drmanac et al. · 2019 [cited by applicant]
US 10473654B1 · Mallick · 2019 [cited by applicant]
US 10571473B2 · Mitra · 2020 [cited by applicant]
US 10605730B2 · Rothberg et al. · 2020 [cited by applicant]
US 10712274B2 · Rothberg et al. · 2020 [cited by applicant]
US 10741382B2 · Sills et al. · 2020 [cited by applicant]
US 10775305B2 · Rothberg et al. · 2020 [cited by applicant]
US 10829816B2 · Staker et al. · 2020 [cited by applicant]
US 10845308B2 · Rothberg et al. · 2020 [cited by applicant]
US 10895534B2 · Finkelstein et al. · 2021 [cited by applicant]
US 10921317B2 · Mallick · 2021 [cited by applicant]
US 10948488B2 · Mallick · 2021 [cited by applicant]
US 11203612B2 · Gremyachinskiy et al. · 2021 [cited by applicant]
US 11970693B2 · Mallick · 2024 [cited by examiner]
US 20030054408A1 · Ravi et al. · 2003 [cited by applicant]
US 20040023413A1 · Opalsky · 2004 [cited by applicant]
US 20040091931A1 · Gold · 2004 [cited by applicant]
US 20040166106A1 · Wang et al. · 2004 [cited by applicant]
US 20040209383A1 · Mn et al. · 2004 [cited by applicant]
US 20050054118A1 · Lebrun · 2005 [cited by applicant]
US 20050095577A1 · Yang et al. · 2005 [cited by applicant]
US 20050287523A1 · Letant et al. · 2005 [cited by applicant]
US 20060014212A1 · Benkovic · 2006 [cited by examiner]
US 20060035220A1 · Tashiro et al. · 2006 [cited by applicant]
US 20060160234A1 · Lopez-Avila et al. · 2006 [cited by applicant]
US 20060263769A1 · Luo et al. · 2006 [cited by applicant]
US 20070188750A1 · Lundquist et al. · 2007 [cited by applicant]
US 20070218503A1 · Mitra · 2007 [cited by applicant]
US 20090161100A1 · Minot et al. · 2009 [cited by applicant]
US 20090214591A1 · Manucharyan et al. · 2009 [cited by applicant]
US 20090247414A1 · Obradovic et al. · 2009 [cited by applicant]
US 20090257952A1 · Cochran et al. · 2009 [cited by applicant]
US 20090311774A1 · Chiou et al. · 2009 [cited by applicant]
US 20100111768A1 · Banerjee et al. · 2010 [cited by applicant]
US 20110065807A1 · Radovic-Moreno et al. · 2011 [cited by applicant]
US 20110263688A1 · Barany et al. · 2011 [cited by applicant]
US 20120077688A1 · Lim et al. · 2012 [cited by applicant]
US 20130310274A1 · Meng et al. · 2013 [cited by applicant]
US 20150160204A1 · Mitra · 2015 [cited by applicant]
US 20150185199A1 · Joo et al. · 2015 [cited by applicant]
US 20150185216A1 · Albert et al. · 2015 [cited by applicant]
US 20150330974A1 · Staker et al. · 2015 [cited by applicant]
US 20160060687A1 · Zhu et al. · 2016 [cited by applicant]
US 20160102344A1 · Niemeyer et al. · 2016 [cited by applicant]
US 20160167413A1 · Furuya · 2016 [cited by applicant]
US 20160310926A1 · Sun et al. · 2016 [cited by applicant]
US 20170044245A1 · Meng et al. · 2017 [cited by applicant]
US 20170175184A1 · Drmanac et al. · 2017 [cited by applicant]
US 20170191051A1 · Nikiforov · 2017 [cited by applicant]
US 20170283868A1 · Beechem et al. · 2017 [cited by applicant]
US 20190195869A1 · Fan et al. · 2019 [cited by applicant]
US 20190204339A1 · Mitra · 2019 [cited by applicant]
US 20200025752A1 · Gopinath et al. · 2020 [cited by applicant]
US 20200025757A1 · Gopinath et al. · 2020 [cited by applicant]
US 20200124615A1 · Ofran · 2020 [cited by examiner]
US 20200158722A1 · Mallick · 2020 [cited by applicant]
US 20200173988A1 · Mallick · 2020 [cited by applicant]
US 20200232994A1 · Mitra · 2020 [cited by applicant]
US 20210101930A1 · Gremyachinskiy et al. · 2021 [cited by applicant]
US 20210223238A1 · Mallick · 2021 [cited by applicant]
US 20210239705A1 · Mallick · 2021 [cited by applicant]
US 20210278400A1 · Mallick · 2021 [cited by applicant]
US 20210355483A1 · Chee et al. · 2021 [cited by applicant]
US 20210373005A1 · Mallick · 2021 [cited by applicant]
US 20220017567A1 · Gremyachinskiy et al. · 2022 [cited by applicant]
US 20220050049A1 · Indermuhle et al. · 2022 [cited by applicant]
US 20220074931A1 · Mallick · 2022 [cited by applicant]
US 20230107579A1 · Klein et al. · 2023 [cited by applicant]
CN 100500865C · 2009 [cited by applicant]
EP 1105529B2 · 2013 [cited by applicant]
EP 2872898B1 · 2016 [cited by applicant]
EP 3498865B1 · 2020 [cited by applicant]
JP 2017504795A · 2017 [cited by applicant]
WO 1999002733A1 · 1999 [cited by applicant]
WO 200146675A2 · 2001 [cited by applicant]
WO 2002086081A2 · 2002 [cited by applicant]
WO 2003099999A2 · 2003 [cited by applicant]
WO 2006135527A2 · 2006 [cited by applicant]
WO 2007117444A2 · 2007 [cited by applicant]
WO 2007120208A3 · 2007 [cited by applicant]
WO 2007123744A3 · 2007 [cited by applicant]
WO 2009012343A2 · 2009 [cited by applicant]
WO 2010065531A1 · 2010 [cited by applicant]
WO 2014078855A1 · 2014 [cited by applicant]
WO 2015034364A1 · 2015 [cited by applicant]
WO 2015097077A2 · 2015 [cited by applicant]
WO 2016174525A1 · 2016 [cited by applicant]
WO 2017127762A1 · 2017 [cited by applicant]
WO 2018102759A1 · 2018 [cited by applicant]
WO 2019036055A2 · 2019 [cited by applicant]
WO 2019195633A1 · 2019 [cited by applicant]
WO 2019236749A2 · 2019 [cited by applicant]
WO 2020106889A1 · 2020 [cited by applicant]
WO 2020108588A1 · 2020 [cited by applicant]
WO 2020223368A1 · 2020 [cited by applicant]
Ogawa et al (Bioorganic & Medicinal Chemistry Letters 14:4001-4) (Year: 2004). [cited by examiner]
Anonymous, “List of protein hydrodynamic diameters,” Dynamic Biosensors, May 17, 2017, Retrieved from Internet: <https://www.dynamic-biosensors.com/project/list-of-protein-hydrodynamicdiameters/>, 3 pages. [cited by applicant]
Arnold et al. “The Majority of Immunogenic Epitopes Generate CD4+ T Cells That are Dependent on MHC Class II—Bound Peptide-Flanking Residues,” Journal of Immunology, 2002, vol. 169, pp. 739-749. [cited by applicant]
Ayoglu et al., “Autoantibody Profiling in Multiple Sclerosis Using Arrays of Human Protein Fragments,” Molecular & Cellular Proteomics, 2013, vol. 12, No. 9, pp. 2657-2672. [cited by applicant]
Blatch et al., “The tetratricopeptide repeat: a structural motif mediating protein-protein interactions,” Bioessays, 1999, vol. 21, No. 11, pp. 932-939. [cited by applicant]
Buenrostro et al., “Quantitative analysis of RNA-protein interactions on a massively parallel array for mapping biophysical and evolutionary landscapes,” Nature Biotechnology, Jun. 2014, vol. 32, No. 6, pp. 562-568. [cited by applicant]
Bunka et al. “Production and Characterization of RNA Aptamers Specific for Amyloid Fibril Epitopes,” Journal Biological Chemistry, Nov. 23, 2007, vol. 282, No. 47, pp. 34500-34509. [cited by applicant]
Buus et al., “High-resolution Mapping of Linear Antibody Epitopes Using Ultrahigh-density Peptide Microarrays,” Molecular & Cellular Proteomics, 2012, vol. 11, No. 12, pp. 1790-1800. [cited by applicant]
Choung et al., “Determination of B-Cell Epitopes in Patients with Celiac Disease: Peptide Microarrays,” PLOS One, Jan. 29, 2016, vol. 11, pp. 1-16. [cited by applicant]
Domenyuk et al., “Plasma Exosome Profiling of Cancer Patients by a Next Generation Systems Biology Approach,” Scientific Reports, 2017, vol. 7, No. 42741, pp. 1-15. [cited by applicant]
Examiner's Interview Summary in U.S. Appl. No. 17/191,632, mailed Nov. 9, 2021, 3 pages. [cited by applicant]
Extended European Search Report in EP17877076.4, mailed Aug. 11, 2020, 7 pages. [cited by applicant]
Extended European Search Report in EP18846671.8, mailed Apr. 23, 2021, 14 pages. [cited by applicant]
Extended European Search Report in EP19781106.0, mailed Nov. 19, 2021, 11 pages. [cited by applicant]
Extended European Search Report in EP19886855.6, mailed Jul. 15, 2022, 8 pages. [cited by applicant]
Fodor et al., “Light-Directed, Spatially Addressable Parallel Chemical Synthesis,” Science Feb. 15, 1991, vol. 251, pp. 767-773. [cited by applicant]
Ford et al. “Degenerate recognition of T cell epitopes: impact of T cell receptor reserve and stability of peptide:MHC complexes,” Molecular Immunology, 2004, vol. 40, pp. 1019-1025. [cited by applicant]
Hung et al., “Large-area spatially ordered arrays of gold nanoparticles directed by lithographically confined DNA origami,” Nature Nanotechnology, Feb. 2010, vol. 5, pp. 121-126. [cited by applicant]
Hunniger et al., “Just in Time-Selection: A Rapid Semiautomated SELEX of DNA Aptamers Using Magnetic Separation and BEAMing,” Analytical Chemistry, 2014, vol. 86, pp. 10940-10947. [cited by applicant]
International Search Report and Written Opinion in PCT/US2017/064322, mailed Apr. 25, 2018, 23 pages. [cited by applicant]
International Search Report and Written Opinion in PCT/US2018/000364, mailed Mar. 22, 2019, 23 pages. [cited by applicant]
International Search Report and Written Opinion in PCT/US2019/025909, mailed Jun. 14, 2019, 18 pages. [cited by applicant]
International Search Report and Written Opinion in PCT/US2019/035654, mailed Nov. 25, 2019, 19 pages. [cited by applicant]
International Search Report and Written Opinion in PCT/US2019/062482, mailed Mar. 3, 2020, 21 pages. [cited by applicant]
International Search Report and Written Opinion in PCT/US2020/030501, mailed Aug. 11, 2020, 13 pages. [cited by applicant]
Kang, H., “The prevention and handling of the missing data,” Korean Journal of Anesthesiology, May 2013, vol. 64, No. 5, pp. 402-406. [cited by applicant]
Laurenson et al., “Development of peptide aptamer microarrays for detection of HPV16 oncoproteins in cell extracts,” Analytical Biochemistry, 2011, vol. 410, pp. 161-170. [cited by applicant]
Lin et al., “Development of a novel peptide microarray for large-scale epitope mapping of food allergens,” Journal of Allergy and Clinical Immunology, Aug. 2009, vol. 124, No. 2, pp. 315-322. [cited by applicant]
Lutz et al., “Efficient construction of therapeutics, bioconjugates, biomaterials and bioactive surfaces using azide-alkyne “click” chemistry,” Advanced Drug Delivery Reviews, 2008, vol. 60, pp. 958-970. [cited by applicant]
McKay et al., “Click Chemistry in Complex Mixtures: Bioorthogonal Bioconjugation,” Chemistry & Biology, Sep. 18, 2014, vol. 21, pp. 1075-1101. [cited by applicant]
Meldal et al., “Cu-Catalyzed Azide-Alkyne Cycloaddition,” Chemical Reviews, 2008, vol. 108, pp. 2952-3015. [cited by applicant]
Nonobe et al., “A tabu search approach to the constraint satisfaction problem as a general problem solver,” European Journal of Operational Research, 1998, vol. 106, pp. 599-623. [cited by applicant]
Notice of Allowance in U.S. Appl. No. 16/426,917, mailed Oct. 1, 2019, 8 pages. [cited by applicant]
Notice of Allowance in U.S. Appl. No. 16/659,132, mailed Jan. 14, 2021, 7 pages. [cited by applicant]
Notice of Allowance in U.S. Appl. No. 16/788,536, mailed Dec. 9, 2020, 7 pages. [cited by applicant]
Notice of Allowance in U.S. Appl. No. 17/062,405, mailed Sep. 30, 2021, 10 pages. [cited by applicant]
Office Action in CN2018800681790.0, mailed Feb. 24, 2023, 9 pages. [cited by applicant]
Office Action in CN2018800681790.0, mailed Sep. 22, 2023, 21 pages. [cited by applicant]
Office Action in JP2020509044, mailed Jan. 24, 2023, 3 pages. [cited by applicant]
Office Action in U.S. Appl. No. 16/659,132, Oct. 8, 2020, 8 pages. [cited by applicant]
Office Action in U.S. Appl. No. 16/788,536, mailed Mar. 10, 2020, 10 pages. [cited by applicant]
Office Action in U.S. Appl. No. 16/788,536, mailed Sep. 24, 2020, 9 pages. [cited by applicant]
Office Action in U.S. Appl. No. 17/062,405, mailed Apr. 14, 2021, 17 pages. [cited by applicant]
Office Action in U.S. Appl. No. 17/062,405, mailed Aug. 24, 2021, 13 pages. [cited by applicant]
Office Action in U.S. Appl. No. 17/191,632, Sep. 17, 2021, 33 pages. [cited by applicant]
Office Action in U.S. Appl. No. 17/191,632, mailed May 12, 2021, 29 pages. [cited by applicant]
Office Action in U.S. Appl. No. 17/390,666, mailed Jan. 28, 2022, 15 pages. [cited by applicant]
Patronov et al., “Peptide binding prediction for the human class II MHC allele HLA-DP2: a molecular docking approach,” BMC Structural Biology, 2011, vol. 11, No. 32, pp. 1-10. [cited by applicant]
Price et al., “On silico peptide microarrays for high-resolution mapping of antibody epitopes and diverse protein-protein interactions,” Nature Medicine, Sep. 2012, vol. 18, No. 9, pp. 1434-1441. [cited by applicant]
Reineke et al., “Epitope Mapping Protocols,” Methods in Molecular Biology, 2009, vol. 524, 145-167 (447 pages). [cited by applicant]
Reyes et al. “Critical role of HLA-DRβ* binding peptides' peripheral flanking residues in fully-protective malaria vaccine development,” Biochemical Biophysical Research Communications, 2017, vol. 489, pp. 339-345. [cited by applicant]
Riccelli et al., “Hybridization of single-stranded DNA targets to immobilized complementary DNA probes: comparison of hairpin versus linear capture probes,” Nucleic Acids Research, 2001, vol. 29, No. 4, pp. 996-1004. [cited by applicant]
Richer et al., “Epitope Identification from Fixed-complexity Random-Sequence Peptide Microarrays,” Molecular & Cellular Proteomics, 2014, vol. 14, No. 1, pp. 136-147. [cited by applicant]
Rothemund et al., “Folding DNA to create nanoscale shapes and patterns,” Nature, Mar. 16, 2006, vol. 440, pp. 297-302. [cited by applicant]
Rusmini et al., “Protein Immobilization Strategies for Protein Biochips,” Biomacromolecules, 2007, vol. 8, pp. 1775-1789. [cited by applicant]
Sant'Angelo et al., “Recognition of core and flanking amino acids of MHC class II-bound peptides by the T cell receptor,” European Journal of Immunology, 2002, vol. 32, pp. 2510-2520. [cited by applicant]
She et al., “Comprehensive and quantitative mapping of RNA-protein interactions across a transcribed eukaryotic genome,” PNAS USA, Apr. 4, 2017, vol. 114, No. 14, pp. 3619-3624. [cited by applicant]
Sjoberg et al., “Validation of affinity reagents using antigen microarrays,” New Biotechnology, Jun. 2012, vol. 29, No. 5, pp. 555-563. [cited by applicant]
Speltz et al., “Design of Protein-Peptide Interaction Modules for Assembling Supramolecular Structures in Vivo and in Vitro,” ACS Chemical Biology, 2015, vol. 10, pp. 2108-2115. [cited by applicant]
Stohr et al., “A 31-residue peptide induces aggregation of tau's microtubule-binding region in cells,” Nature Chemistry, Sep. 2017, vol. 9, No. 9, pp. 874-881. [cited by applicant]
Tessler, L., “Digital Protein Analysis: Technologies for Protein Diagnostics and Proteomics through Single-Molecule Detection,” All Theses and Dissertations, Jan. 2011, Retrieved from Internet: <https://openscholarship.… [cited by applicant]
Wikipedia, “(3-Aminopropyl)triethoxysilane,” Wikipedia.org, Apr. 5, 2019, 2 pages. [cited by applicant]
Wilson et al., “Single-Step Selection of Bivalent Aptamers Validated by Comparison with SELEX Using High-Throughput Sequencing,” PLOS One, Jun. 2014, vol. 9, No. 6, pp. 1-11. [cited by applicant]
Zandian et al., “Whole-Proteome Peptide Microarrays for Profiling Autoantibody Repertoires within Multiple Sclerosis and Narcolepsy,” Journal of Proteome Research, 2017, vol. 16, pp. 1300-1314. [cited by applicant]
Office Action in CN201880068179.0, mailed Mar. 26, 2024, 25 pages. [cited by applicant]
Menendez A., el al., “Human immunodeficiency virus type 1-neutralizing monoclonal antibody 2F5 is multispecific for sequences flanking the DKW core epitope”. Journal of molecular biology. Apr. 23, 2004;338(2):311-327. [cited by applicant]
Office Action in EP18 846 671.8, mailed Jun. 19, 2024, 12 pages. [cited by applicant]
Office Action in CN201880068179.0, mailed Jun. 24, 2024, 23 pages. [cited by applicant]
Office Action issued in corresponding Indian patent application No. 202017008442, dated Nov. 6, 2025, 10 pages. [cited by applicant]